Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Inhaled Treprostinil Clear all
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

NCT02276872
View directory record Official record
Conditions
PAH
Interventions
oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
7 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 24, 2026, 9:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

NCT06193031
View directory record Official record
Conditions
Healthy Volunteers
Interventions
C16TR, Placebo, Tyvaso®
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 24, 2026, 9:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

NCT04041648
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System, Placebo Solution
Drug · Device · Other
Lead sponsor
Pharmosa Biopharm Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 24, 2026, 9:42 AM EDT
Recruiting Early Phase 1 Interventional

Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)

NCT07837830
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Treprostinil, Standard of Care
Drug · Other
Lead sponsor
Valley Health System
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 24, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604
View directory record Official record
Conditions
Primary Pulmonary Hypertension
Interventions
LIQ861 Inhaled Treprostinil
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 24, 2026, 9:42 AM EDT
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 24, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension

NCT02471183
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Selexipag
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 24, 2026, 9:42 AM EDT
Terminated Phase 4 Interventional

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

NCT00458042
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
treprostinil sodium
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2007 · Synced Sep 24, 2026, 9:42 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Santa Barbara, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 24, 2026, 9:42 AM EDT
Terminated Phase 2 Interventional Results available

Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso

NCT02178566
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 24, 2026, 9:42 AM EDT
Recruiting Phase 3 Interventional

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07234032
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Naples, Florida • Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 24, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Results available

A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).

NCT01305252
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
treprostinil inhalations, tadalafil
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 69 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Stanford, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 24, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Results available

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

NCT00741819
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 24, 2026, 9:42 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

NCT04691154
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
Interventions
L606 inhalation suspension
Combination Product
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 24, 2026, 9:42 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

NCT05649748
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 24, 2026, 9:42 AM EDT
Completed Phase 3 Interventional

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

NCT04708782
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 24, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Beraprost-314d Added-on to Tyvaso® (BEAT)

NCT01908699
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Beraprost Sodium 314d Modified Release Tablets, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 24, 2026, 9:42 AM EDT
Terminated No phase listed Observational

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

NCT01494896
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Jacksonville, Florida • Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 24, 2026, 9:42 AM EDT
Recruiting Phase 2 Interventional

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

NCT07333183
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions
inhaled mosliciguat, Dry Powder Inhaler
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 24, 2026, 9:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

NCT06091579
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 24, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension

NCT05564637
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults
Interventions
Treprostinil, Right Heart Catheterization (RHC) while exercising, Optional Muscle Biopsy
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 24, 2026, 9:42 AM EDT
Completed Phase 4 Interventional Results available

Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

NCT01268553
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Tucson, Arizona • San Francisco, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 24, 2026, 9:42 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Los Angeles, California • Santa Barbara, California • Torrance, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 24, 2026, 9:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

NCT02630316
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions
Inhaled Treprostinil, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
96
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 24, 2026, 9:42 AM EDT